Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his decision to retire from the Board of Directors. Dr. Homcy co-founded the Company in 2003...
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will present a corporate overview at Cowen and Company’s 39 th Annual Heal...
Portola Pharmaceuticals Inc (PTLA) Q4 2018 Earnings Conference Call March 01, 2019 08:30 AM ET Company Participants Cara Miller - Vice President of Investor Relations and Corporate Communications Scott Garland - President and Chief Executive Officer Mardi Dier - Chief Financial O...
Puma Biotechnology (NYSE: PBYI ) +30% on Q4 earnings . More news on: Puma Biotechnology, Inc., Funko, Inc., The Gap, Inc., Stocks on the move, Read more ...
Portola Pharmaceuticals ( PTLA ) Q4 results : Revenues: $15.3M (+56.1%); Product revenue: $14.1M; Collaboration and license revenue: $1.2M. More news on: Portola Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Portola Pharmaceuticals (NASDAQ: PTLA ): Q4 Non-GAAP EPS of -$1.04 beats by $0.07 ; GAAP EPS of -$1.34 misses by $0.23 . More news on: Portola Pharmaceuticals, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
– Fourth Quarter Andexxa ® Revenues of $14.0 Million; Third Consecutive Quarter of Strong Revenues – – Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early May – – Sign...
SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that it has entered into a $125 million loan agreement with HealthCare Royalty Partners (HCR) and investment funds manager Athyrium Capital Management, LP. ...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Portola Pharmaceuticals' (NASDAQ: PTLA ) Factor Xa reversal agent Ondexxya (andexanet alfa). More news on: Portola Pharmaceuticals, Healthcare stocks news, Stocks on the move, ...
SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authoriz...
News, Short Squeeze, Breakout and More Instantly...
Portola Pharmaceuticals Inc. Company Name:
PTLA Stock Symbol:
NASDAQ Market:
Portola Pharmaceuticals Inc. Website:
SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and othe...
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagula...
SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to su...